Daniel M. Frendl

Dr. Daniel M. Frendl, a urologist at the Mayo Clinic in Arizona, dives into the complexities of prostate cancer screening. He unpacks the controversies surrounding PSA testing and how it revolutionized cancer diagnosis rates in the '90s. Discussions include the role of the digital rectal exam and the impact of updated screening guidelines. Frendl emphasizes tailored screening starting at age 45, particularly for high-risk groups. He also highlights advancements like MRI-guided biopsy to improve specificity in detecting prostate cancer.